ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO464

Fasting Blood Glucose Level and All-Cause Mortality in Peritoneal Dialysis Patients

Session Information

Category: Dialysis

  • 702 Dialysis: Home Dialysis and Peritoneal Dialysis


  • Lim, Sojin, Kyung Hee University, Seoul, Korea (the Republic of)
  • Jeong, Kyung hwan, Kyung Hee University, Seoul, Korea (the Republic of)
  • Hwang, Hyeon Seok, Kyung Hee University, Seoul, Korea (the Republic of)
  • Kim, Jin sug, Kyung Hee University, Seoul, Korea (the Republic of)
  • Yoon, Soo-Young, Kyung Hee University, Seoul, Korea (the Republic of)
  • Kim, Jongho, Kyung Hee University, Seoul, Korea (the Republic of)
  • Kim, Geon Woo, Kyung Hee University, Seoul, Korea (the Republic of)

Group or Team Name

  • Division of Nephrology, Department of Internal Medicine, Kyung Hee University

Dialysis solutions that are used in Peritoneal dialysis (PD) patients contain high concentration of glucose, so the issue of glycemic control is especially important for PD patients. Fasting Blood Glucose (FBG) is the most widely used blood glucose index in the clinical field because it is a principal indicator of daily status of glycemic status and it can help determine the anti-diabetes management. While these strength of FBG monitoring is considered as critical component for ideal glycemic control, there is no consistent evidence to support the optimal level of FBG in PD patients.


We used data from the National Health Insurance database of Korea, screening 29,266 patients who received maintenance PD treatment between 2002 and 2018. A total of 943 patients were included, who diagnosed diabetes and received national health screening examination. The primary endpoint in this study was the association between time–updated FBG and all-cause mortality.


During a median follow-up of 6.55 years, we analyzed 943 patients divided into 6 groups according to the FBG level. The mean age was 52.6 years and 63.6% was male. In addition, the mean FBG was 128.8 mg/dL. In the time-varying Cox models, 125 mg/dL≤ FBG< 150 mg/dL group showed a significant increase in all-cause mortality (HR, 1.27; 95% confidence interval [CI], 1.02-1.58; p = 0.032) compared with 80 mg/dL≤ FBG <100 mg/dL group as the reference. Similar results were observed with 150 mg/dL≤ FBG <180 mg/dL and FBG ≥180 mg/dL groups (HR, 1.35; 95% CI, 1.02-1.58; p = 0.021/ HR, 1.61; 95% CI, 1.32-1.96; p <0.001, respectively). Subgroup analysis revealed that patients who had age of <65 years, female gender, higher body mass index or less comorbidity score were significantly associated with higher mortality risk at FBG > 100 mg/dL, compared to those with 80 mg/dL≤ FBG <100 mg/dL.


Peritoneal dialysis Patients with 80≤ FBG <100 mg/dL were significantly associated with lower risk of all-cause mortality than those with FBG <80 mg/dL or ≥ 100 mg/dL. In addition, patient-specific conditions allowed even tighter FBG target for lower risk of mortality.


  • Government Support – Non-U.S.